ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TERN Terns Pharmaceuticals Inc

5.49
-0.27 (-4.69%)
Last Updated: 18:13:10
Delayed by 15 minutes
Share Name Share Symbol Market Type
Terns Pharmaceuticals Inc NASDAQ:TERN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.27 -4.69% 5.49 5.49 5.50 5.865 5.46 5.82 1,216,296 18:13:10

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

30/05/2024 1:05pm

GlobeNewswire Inc.


Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart


From Dec 2023 to Dec 2024

Click Here for more Terns Pharmaceuticals Charts.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June.

Jefferies Global Healthcare Conference Format: Fireside Chat         Date and Time: Wednesday, June 5, 2024 at 5:00 p.m ET Location: Marriott Marquis, New York City

Goldman Sachs 45th Annual Global Healthcare Conference Format: Fireside Chat Date and Time: Tuesday, June 11, 2024 at 3:20 p.m. ET Location: Loews Miami Beach Hotel, Miami

Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.

About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.

Contacts for Terns

InvestorsJustin Ng investors@ternspharma.com

MediaJenna UrbanBerry & Company Public Relationsmedia@ternspharma.com

1 Year Terns Pharmaceuticals Chart

1 Year Terns Pharmaceuticals Chart

1 Month Terns Pharmaceuticals Chart

1 Month Terns Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock